Methotrexate Injection Now Available for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Clinical outcomes of and treatment for Kawasaki disease were found to be distinct for Black and White children.
Study authors identified cross-cutting disease factors affecting the mental health of youth with rheumatologic disease.
During the COVID-19 pandemic, healthcare teams have realized the potential of telemedicine in pediatric rheumatology practices.
Researchers analyzed the response to biologic treatment in juvenile idiopathic arthritis based on the timing of initiation of the treatment.
Researchers investigated the feasibility, acceptability, and diagnostic performance of imaging-based surveillance for uveitis.
Researchers determined the feasibility of elastography ultrasound in the assessment of pediatric-onset localized scleroderma.
Researchers determined the temporal association between arthritis and uveitis activity in children with juvenile idiopathic arthritis associated with uveitis.
A group of rheumatologists and researchers analyzed how the COVID-19 pandemic has affected pediatric rheumatology practice.
The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.